Affimed N.V.
NASDAQ:AFMD
Overview | Financials
Company Name | Affimed N.V. |
Symbol | AFMD |
Currency | USD |
Price | 1.19 |
Market Cap | 18,120,725 |
Dividend Yield | 0% |
52-week-range | 1.144 - 8.95 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Adi Hoess M.D., Ph.D. |
Website | https://www.affimed.com |
An error occurred while fetching data.
About Affimed N.V.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD